CTnl+Myo+CK-MB Diagnostic Reagents For Fully Automated Immunoassay Analyzer IVD Reagents In POClia

POCT Reagents of cTnl+Myo+CK-MB: Myocardial infarction and myocardial injury detection indicators

Clinical Significance of cTnl:
AMI diagnosis "gold standard"
AMI to determine infarct size and carry out risk stratification

Clinical Significance of Myo:
The most important indicator for early negative exclusion of AMI.
AMI recurrence detection, the most sensitive indicator for reperfusion therapy detection.

Clinical Significance of CK-MB:
Early diagnosis of AMI and risk stratification.
The most valuable marker of non-ST-segment elevation AMI

Acute myocardial injury is a very common clinical disease, including acute coronary syndrome (ACS), various acute myocardial infarction (AMI), unstable angina and myocarditis, which seriously endanger human health and quality of life.

Myocardial infarction refers to the reduction or interruption of coronary blood supply on the basis of coronary artery disease, causing the corresponding severe and persistent acute ischemic necrosis of the myocardium. The clinical manifestations are sudden, severe and persistent retrosternal pain, characteristic electrocardiogram dynamic evolution and increase of cardiac markers, and complications such as arrhythmia, heart failure, and shock may occur, which are often life-threatening. Symptoms of myocardial infarction are chest pain and tightness in the chest. The incentives are generally, excessive fatigue, emotional agitation, overeating, major surgery or hemorrhagic shock. In terms of age, middle-aged men between the ages of 45 and 60 are at high risk for myocardial infarction.

In recent years, more and more products have been combined to detect the three indicators of creatine kinase isoenzyme MB, cardiac troponin and myoglobin, and they are gradually accepted by the clinic. item".

Other Kind of Reagents we can provide:

Zecen Biotech CO., LTD., founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents. Zecen focus on the Chemiluminescent immunoassay (CLIA) field. With all products CE marked, our market presence currently spreads from across China to other countries including India, Switzerland, Russia etc., Zecen is expanding its footprint to become a global brand.

Zecen is the only enterprise with independent intellectual property rights in the entire chemiluminescence industry chain in China, including reagent, instrument, magnetic microbead, and reagent raw material. Our current products include more than 100 assays, from thyroid, inflammation, diabetes, tumer markers, immune disorders, hormones to cardiac markers. Our ever-expanding test menu helps our customers and collaborators keep up with the demands of healthcare sector. Zecen is striving for innovation and perfection to deliver the best products to the customers.

As a manufacturer, Zecen provide the OEM, ODM and other customized service of all products. We have the core R&D centers and innovative ability to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. High-quality sales and after-sales links provide the more intimate service. The patent and CE certification give us the confident sending all over the world, and more than 50 companys in the requiement of customized and have a long term coorperation with Zecen.